MYRIAD GENETICS INC (MYGN) Stock Fundamental Analysis

NASDAQ:MYGN • US62855J1043

4.49 USD
-0.04 (-0.88%)
At close: Feb 13, 2026
4.49 USD
0 (0%)
After Hours: 2/13/2026, 8:27:33 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to MYGN. MYGN was compared to 522 industry peers in the Biotechnology industry. Both the profitability and financial health of MYGN have multiple concerns. MYGN is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year MYGN was profitable.
  • MYGN had a negative operating cash flow in the past year.
  • MYGN had negative earnings in each of the past 5 years.
  • In multiple years MYGN reported negative operating cash flow during the last 5 years.
MYGN Yearly Net Income VS EBIT VS OCF VS FCFMYGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M

1.2 Ratios

  • MYGN's Return On Assets of -55.01% is in line compared to the rest of the industry. MYGN outperforms 45.51% of its industry peers.
  • MYGN's Return On Equity of -107.43% is in line compared to the rest of the industry. MYGN outperforms 43.59% of its industry peers.
Industry RankSector Rank
ROA -55.01%
ROE -107.43%
ROIC N/A
ROA(3y)-14.9%
ROA(5y)-12.19%
ROE(3y)-21.47%
ROE(5y)-17.79%
ROIC(3y)N/A
ROIC(5y)N/A
MYGN Yearly ROA, ROE, ROICMYGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20 -30

1.3 Margins

  • With an excellent Gross Margin value of 70.36%, MYGN belongs to the best of the industry, outperforming 81.64% of the companies in the same industry.
  • In the last couple of years the Gross Margin of MYGN has declined.
  • MYGN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 70.36%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.7%
GM growth 5Y-1.76%
MYGN Yearly Profit, Operating, Gross MarginsMYGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • MYGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for MYGN has been increased compared to 1 year ago.
  • The number of shares outstanding for MYGN has been increased compared to 5 years ago.
  • Compared to 1 year ago, MYGN has a worse debt to assets ratio.
MYGN Yearly Shares OutstandingMYGN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
MYGN Yearly Total Debt VS Total AssetsMYGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

  • Based on the Altman-Z score of -0.35, we must say that MYGN is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of MYGN (-0.35) is comparable to the rest of the industry.
  • A Debt/Equity ratio of 0.32 indicates that MYGN is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.32, MYGN is doing worse than 67.50% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.32
Debt/FCF N/A
Altman-Z -0.35
ROIC/WACCN/A
WACC12.09%
MYGN Yearly LT Debt VS Equity VS FCFMYGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M 1B

2.3 Liquidity

  • A Current Ratio of 2.33 indicates that MYGN has no problem at all paying its short term obligations.
  • MYGN has a Current ratio of 2.33. This is in the lower half of the industry: MYGN underperforms 72.08% of its industry peers.
  • MYGN has a Quick Ratio of 2.12. This indicates that MYGN is financially healthy and has no problem in meeting its short term obligations.
  • MYGN has a Quick ratio of 2.12. This is in the lower half of the industry: MYGN underperforms 72.66% of its industry peers.
Industry RankSector Rank
Current Ratio 2.33
Quick Ratio 2.12
MYGN Yearly Current Assets VS Current LiabilitesMYGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The earnings per share for MYGN have decreased strongly by -64.29% in the last year.
  • Measured over the past years, MYGN shows a very strong growth in Earnings Per Share. The EPS has been growing by 86.63% on average per year.
  • MYGN shows a small growth in Revenue. In the last year, the Revenue has grown by 0.21%.
  • Measured over the past years, MYGN shows a decrease in Revenue. The Revenue has been decreasing by -0.32% on average per year.
EPS 1Y (TTM)-64.29%
EPS 3Y86.63%
EPS 5YN/A
EPS Q2Q%-100%
Revenue 1Y (TTM)0.21%
Revenue growth 3Y6.64%
Revenue growth 5Y-0.32%
Sales Q2Q%-3.56%

3.2 Future

  • Based on estimates for the next years, MYGN will show a very strong growth in Earnings Per Share. The EPS will grow by 29.27% on average per year.
  • The Revenue is expected to grow by 4.40% on average over the next years.
EPS Next Y-98.93%
EPS Next 2Y-19.79%
EPS Next 3Y10.17%
EPS Next 5Y29.27%
Revenue Next Year-2.05%
Revenue Next 2Y1.67%
Revenue Next 3Y2.85%
Revenue Next 5Y4.4%

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
MYGN Yearly Revenue VS EstimatesMYGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M 1B
MYGN Yearly EPS VS EstimatesMYGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5 1 1.5

More info and screens

Find the best growth stocksShow best growing peers

2

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 89.80, which means the current valuation is very expensive for MYGN.
  • Compared to the rest of the industry, the Price/Earnings ratio of MYGN indicates a rather cheap valuation: MYGN is cheaper than 89.67% of the companies listed in the same industry.
  • When comparing the Price/Earnings ratio of MYGN to the average of the S&P500 Index (26.68), we can say MYGN is valued expensively.
  • Based on the Price/Forward Earnings ratio of 53.68, the valuation of MYGN can be described as expensive.
  • Based on the Price/Forward Earnings ratio, MYGN is valued cheaper than 89.48% of the companies in the same industry.
  • MYGN's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 28.06.
Industry RankSector Rank
PE 89.8
Fwd PE 53.68
MYGN Price Earnings VS Forward Price EarningsMYGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MYGN Per share dataMYGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-19.79%
EPS Next 3Y10.17%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • MYGN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MYRIAD GENETICS INC

NASDAQ:MYGN (2/13/2026, 8:27:33 PM)

After market: 4.49 0 (0%)

4.49

-0.04 (-0.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-03
Earnings (Next)03-03
Inst Owners98.58%
Inst Owner Change-92.86%
Ins Owners2.58%
Ins Owner Change1.42%
Market Cap418.51M
Revenue(TTM)825.30M
Net Income(TTM)-400.50M
Analysts53.33
Price Target7.85 (74.83%)
Short Float %11.45%
Short Ratio10.59
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)363.83%
Min EPS beat(2)100%
Max EPS beat(2)627.66%
EPS beat(4)3
Avg EPS beat(4)193.66%
Min EPS beat(4)-2.9%
Max EPS beat(4)627.66%
EPS beat(8)7
Avg EPS beat(8)222.43%
EPS beat(12)10
Avg EPS beat(12)156.03%
EPS beat(16)13
Avg EPS beat(16)126.64%
Revenue beat(2)1
Avg Revenue beat(2)0.96%
Min Revenue beat(2)-1.57%
Max Revenue beat(2)3.49%
Revenue beat(4)1
Avg Revenue beat(4)-1.19%
Min Revenue beat(4)-4.24%
Max Revenue beat(4)3.49%
Revenue beat(8)3
Avg Revenue beat(8)-0.37%
Revenue beat(12)6
Avg Revenue beat(12)0.38%
Revenue beat(16)8
Avg Revenue beat(16)-0.17%
PT rev (1m)-4.51%
PT rev (3m)5%
EPS NQ rev (1m)-5.05%
EPS NQ rev (3m)-505.26%
EPS NY rev (1m)-57.23%
EPS NY rev (3m)-70.56%
Revenue NQ rev (1m)0.08%
Revenue NQ rev (3m)-0.34%
Revenue NY rev (1m)0.03%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 89.8
Fwd PE 53.68
P/S 0.51
P/FCF N/A
P/OCF N/A
P/B 1.12
P/tB 2.65
EV/EBITDA N/A
EPS(TTM)0.05
EY1.11%
EPS(NY)0.08
Fwd EY1.86%
FCF(TTM)-0.32
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS8.85
BVpS4
TBVpS1.7
PEG (NY)N/A
PEG (5Y)N/A
Graham Number2.12
Profitability
Industry RankSector Rank
ROA -55.01%
ROE -107.43%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 70.36%
FCFM N/A
ROA(3y)-14.9%
ROA(5y)-12.19%
ROE(3y)-21.47%
ROE(5y)-17.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.7%
GM growth 5Y-1.76%
F-Score5
Asset Turnover1.13
Health
Industry RankSector Rank
Debt/Equity 0.32
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 48.14%
Cap/Sales 3.28%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.33
Quick Ratio 2.12
Altman-Z -0.35
F-Score5
WACC12.09%
ROIC/WACCN/A
Cap/Depr(3y)84.3%
Cap/Depr(5y)59.15%
Cap/Sales(3y)6.65%
Cap/Sales(5y)4.83%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-64.29%
EPS 3Y86.63%
EPS 5YN/A
EPS Q2Q%-100%
EPS Next Y-98.93%
EPS Next 2Y-19.79%
EPS Next 3Y10.17%
EPS Next 5Y29.27%
Revenue 1Y (TTM)0.21%
Revenue growth 3Y6.64%
Revenue growth 5Y-0.32%
Sales Q2Q%-3.56%
Revenue Next Year-2.05%
Revenue Next 2Y1.67%
Revenue Next 3Y2.85%
Revenue Next 5Y4.4%
EBIT growth 1Y13.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year46.92%
EBIT Next 3Y32.16%
EBIT Next 5Y15.6%
FCF growth 1Y78.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y96.09%
OCF growth 3YN/A
OCF growth 5YN/A

MYRIAD GENETICS INC / MYGN FAQ

What is the ChartMill fundamental rating of MYRIAD GENETICS INC (MYGN) stock?

ChartMill assigns a fundamental rating of 3 / 10 to MYGN.


What is the valuation status of MYRIAD GENETICS INC (MYGN) stock?

ChartMill assigns a valuation rating of 2 / 10 to MYRIAD GENETICS INC (MYGN). This can be considered as Overvalued.


How profitable is MYRIAD GENETICS INC (MYGN) stock?

MYRIAD GENETICS INC (MYGN) has a profitability rating of 2 / 10.


Can you provide the financial health for MYGN stock?

The financial health rating of MYRIAD GENETICS INC (MYGN) is 3 / 10.